Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 8/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30401813 | 1.00 | RAD52 (0.74) | RAD52KMT2AMEN1MAPTNPC1 | |
| SCHEMBL25300551 | 0.98 | KMT2A (0.76) | RAD52KMT2AMEN1MAPTNPC1 | |
| SCHEMBL25811381 | 0.96 | KMT2A (0.78) | RAD52KMT2AMEN1MAPTNPC1 | |
| SCHEMBL25811305 | 0.92 | RAD52 (0.87) | RAD52KMT2AMEN1MAPTNPC1 | |
| SCHEMBL25811288 | 0.90 | KMT2A (0.79) | RAD52KMT2AMEN1MAPTNPC1 | |
| SCHEMBL25811765 | 0.89 | KMT2A (0.71) | RAD52KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL25811716 | 0.87 | KMT2A (0.66) | RAD52KMT2AMEN1MAPTHPGD | |
| SCHEMBL25811257 | 0.85 | RAD52 (0.66) | RAD52KMT2AMEN1MAPTNPC1 | |
| SCHEMBL30312306 | 0.85 | RAD52 (0.66) | RAD52KMT2AMEN1MAPTNPC1 | |
| SCHEMBL25812228 | 0.82 | KMT2A (0.64) | RAD52KMT2AMEN1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218573-A1 | INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | GALYAN BIO INC (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230218573-A1 | INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | GALYAN BIO INC (US) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218573-A1 | INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | HTT, HYPK, PARK7 | RAD52 1790/4885KMT2A 981/4885MEN1 3841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.